Navrogen Inc. is a biopharmaceutical company focused on the targeted treatment of cancer. Navrogen is currently working on enhancing the immune system to fight cancer by removing the effect of factors produced or induced by tumor cells which inhibit the cancer-fighting humoral immune system.
Location: United States, Pennsylvania, Thornbury Township
Employees: 1-10
Total raised: $6.4M
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | Ben Frankl... | sep.benfra... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.09.2021 | Seed | $3.2M | - |
| 17.09.2019 | - | $3.2M | - |
Mentions in press and media 17
| Date | Title | Description |
| 14.07.2026 | Navrogen Awarded Patent for NAV-001 Anti-Mesothelin Antibody-Drug Conjugate (ADC) Targeting Difficult-to-Treat Cancers | HIO factor mechanism of ADC suppressed efficacy The patent covers the design and use of NAV-001 ADC to treat cancers where the therapeutic efficacy of antibody-based drugs, including ADCs, is immunosuppressed NAV-001 has been developed for ... |
| 07.07.2026 | Navrogen Publishes Breakthrough on NAV-005, A CA125 Antagonist That Improves Antibody Cancer Therapy and ADC Efficacy | NAV-005 mechanism to enhance ADC efficacy in Humoral Immuno-Oncology positive cancer target cells The research highlights how NAV-005 overcomes the immunosuppressive effects that tumor-produced CA125 has on antibodies and ADCs to enhance th... |
| 08.09.2025 | Navrogen Awarded Nat'l Cancer Institute Grant to Develop Antagonists to Treat Humoral Immuno-Oncology Positive Cancers | Navrogen Awarded National Cancer Institute Grant to Develop Antagonists to Treat Humoral Immuno-Oncology (HIO) Positive Cancers CHEYNEY, PA, UNITED STATES, September 8, 2025 /EINPresswire.com/ -- Cheyney, PA, September 8, 2025 - Navrogen, I... |
| 05.05.2025 | Navrogen Announces Publication on the CA125-Refractory NAV-006 Ab Treatment of Immunosuppressed Follicular Lymphoma | Navrogen Inc Announces Publication on the CA125-Refractory NAV-006 Antibody for the Treatment of Immunosuppressed Follicular Lymphoma CHEYNEY, PA, UNITED STATES, May 5, 2025 /EINPresswire.com/ -- Cheyney, PA, May, 5 2025 - Navrogen, Inc., a... |
| 26.03.2025 | Navrogen Announces Publication and Presentation at the AACR Annual Meeting of a Novel Antibody Engineering Platform | Navrogen Inc Announces Publication of a Novel Antibody Engineering Platform CHEYNEY, PA, UNITED STATES, March 26, 2025 /EINPresswire.com/ -- Navrogen, Inc., a biopharmaceutical company specialized in developing antibody-based therapies for ... |
| 01.05.2023 | Money Moves: Motobyo launched two crowdfunding campaigns to raise $4M | Money Moves is a column where we chart the funding raises of tech companies across the region. Have a tip? Email us at philly@technical.ly. Motobyo seeks $4 million raise with crowdfunding campaigns Motobyo, the Horsham-based startup with a... |
| 27.03.2023 | Navrogen and National Cancer Institute Establish Collaboration Study Impact Immunosuppressive Factor CA125 on Rituximab | Navrogen and the National Cancer Institute Establish Collaboration to Study the Impact of Immunosuppressive Factor CA125 on Rituximab Effectiveness CHEYNEY, PA, UNITED STATES, March 27, 2023/EINPresswire.com/ -- Cheyney, PA, March 27th, 202... |
| 18.10.2021 | Ben Franklin Approved $2.1M in 12 Early Stage Companies | |
| 16.09.2021 | Navrogen Enters Into CRADA With USAMRIID To Test Proprietary Small Molecule NK Cell Activators Against SARS-COV-2 Infection | The CRADA is focused on testing Navrogen’s small molecule NK cell activating agents on suppressing propagation of SARS-COV-2. Researchers at USAMRIID have developed model systems to test agents capable of suppressing SARS-COV-2 infection an... |
| 03.09.2021 | Navrogen Raises $3M in Venture Capital Financing to Advance Cancer Therapy Platform | Navrogen Inc. plans to use the proceeds from the seed funding round to support its technology platform being used to develop potential new therapies targeting immunosuppressed cancers and immune-mediated diseases. The financing was led by T... |
Show more